Elevated p53 expression levels correlate with tumor progression and poor prognosis in patients exhibiting esophageal squamous cell carcinoma

Huang,Kate; Chen,Lin; Zhang,Jiliang; Wu,Zhi; Lan,Linhua; Wang,Lu; Lu,Bin; Liu,Yongzhang

doi:10.3892/ol.2014.2343

Elevated p53 expression levels correlate with tumor progression and poor prognosis in patients exhibiting esophageal squamous cell carcinoma

Authors:
- Kate Huang
- Lin Chen
- Jiliang Zhang
- Zhi Wu
- Linhua Lan
- Lu Wang
- Bin Lu
- Yongzhang Liu
View Affiliations

Affiliations: Department of Pathology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325035, P.R. China, Department of Biochemistry and Molecular Biology, Attardi Institute of Mitochondrial Biomedicine, Zhejiang Provincial Key Laboratory of Medical Genetics, School of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, P.R. China
Published online on: July 11, 2014 https://doi.org/10.3892/ol.2014.2343
Pages: 1441-1446

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Esophageal squamous cell carcinoma (ESCC) is the most common histological subtype of esophageal cancer and one of the most aggressive types of malignancy, with a high rate of mortality. Early diagnosis and treatment may improve the prognosis of ESCC and, thus, survival rates. As a significant tumor suppressor, p53 is closely associated with apoptosis and the differentiation of cancer cells. The present study evaluated the expression levels of the p53 protein and the clinical significance in patients presenting with ESCC. The p53 protein expression level of 64 paired ESCC and tumor‑adjacent normal tissues was evaluated using western blot analysis. In addition, immunohistochemistry (IHC) was performed to detect the p53 expression level in specimens from 118 paraffin‑embedded cancerous tissues. The correlation of the p53 expression level with the clinicopathological parameters and prognosis of the ESCC patients was also analyzed. The p53 protein was identified to be highly expressed in the ESCC tissue, with western blot analysis demonstrating that the expression level of p53 in the cancerous tissue was 1.89 times that of the tumor‑adjacent normal tissue (P<0.001); furthermore, IHC indicated that there was a marked positive expression of p53 in the ESCC tissue (49.15%). The expression level of p53 protein was identified to be significantly correlated with the tumor grade (P<0.001), N stage (P=0.010). Additionally, the higher level of p53 expression was found to be associated with a poor survival rate in the ESCC patients (P=0.0404). The univariate analysis showed that the survival time of patients was significantly correlated with the T stage (RR=3.886, P<0.001), N stage (lymph node metastasis; RR=3.620, P<0.001) and TNM stage (RR=3.576, P<0.001). Furthermore, the multivariate analysis revealed that the T stage (RR=3.988, P<0.001) and N stage (RR=4.240, P=0.004) significantly influenced the overall survival of the ESCC patients.

View Figures

View References

1	Song QK, Li J, Jiang HD, He YM, Zhou XQ and Huang CY: Esophageal cancer mortality during 2004–2009 in Yanting County, China. Asian Pac J Cancer Prev. 13:5003–5006. 2012.
2	Blot WJ: Esophageal cancer trends and risk factors. Semin Oncol. 21:403–410. 1994.
3	Brooks-Brunn JA: Esophageal cancer: an overview. Medsurg Nurs. 9:248–254. 2000.
4	Cho H, Ha SY, Park SH, Park K and Chae YS: Role of p53 gene mutation in tumor aggressiveness of intracranial meningiomas. J Korean Med Sci. 14:199–205. 1999.
5	Murata A, Baba Y, Watanabe M, et al: p53 immunohistochemical expression and patient prognosis in esophageal squamous cell carcinoma. Med Oncol. 30:7282013.
6	Cardin R, Piciocchi M, Tieppo C, et al: Oxidative DNA damage in Barrett mucosa: correlation with telomeric dysfunction and p53 mutation. Ann Surg Oncol. 20(Suppl 3): S583–S589. 2013.
7	Di Agostino S, Strano S and Blandino G: Gender, mutant p53 and PML: a growing ‘affaire’ in tumor suppression and oncogenesis. Cell Cycle. 12:1824–1825. 2013.
8	Guinan P, Sobin LH, Algaba F, et al: TNM staging of renal cell carcinoma: Workgroup No 3. Union International Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer. 80:992–993. 1997.
9	Sobin LH and Fleming ID: TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer. 80:1803–1804. 1997.
10	Nocito A, Bubendorf L, Tinner EM, et al: Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade. J Pathol. 194:349–357. 2001.
11	Nie X, Li M, Lu B, et al: Down-regulating overexpressed human Lon in cervical cancer suppresses cell proliferation and bioenergetics. PloS One. 8:e810842013.
12	Remmele W and Stegner HE: Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe. 8:138–140. 1987.(In German).
13	Cheng AN, Jiang SS, Fan CC, et al: Increased Cdc7 expression is a marker of oral squamous cell carcinoma and overexpression of Cdc7 contributes to the resistance to DNA-damaging agents. Cancer Lett. 337:218–225. 2013.
14	Bolander A, Agnarsdóttir M, Strömberg S, et al: The protein expression of TRP-1 and galectin-1 in cutaneous malignant melanomas. Cancer genomics Proteomics. 5:293–300. 2008.
15	Grelewski PG and Bar JK: The role of p53 protein and MMP-2 tumor/stromal cells expression on progressive growth of ovarian neoplasms. Cancer Invest. 31:472–479. 2013.
16	Lee JY, Kim HJ, Yoon NA, et al: Tumor suppressor p53 plays a key role in induction of both tristetraprolin and let-7 in human cancer cells. Nucleic Acids Res. 41:5614–5625. 2013.
17	Krell J, Frampton AE, Colombo T, et al: The p53 miRNA interactome and its potential role in the cancer clinic. Epigenomics. 5:417–428. 2013.
18	Gu Z, Jiang J, Tan W, et al: p53/p21 Pathway involved in mediating cellular senescence of bone marrow-derived mesenchymal stem cells from systemic lupus erythematosus patients. Clin Dev Immunol. 2013:1342432013.
19	Zhou Y and Ho WS: Combination of liquiritin, isoliquiritin and isoliquirigenin induce apoptotic cell death through upregulating p53 and p21 in the A549 non-small cell lung cancer cells. Oncol Rep. 31:298–304. 2014.
20	Formigari A, Gregianin E and Irato P: The effect of zinc and the role of p53 in copper-induced cellular stress responses. J Appl Toxicol. 33:527–536. 2013.
21	Biramijamal F, Allameh A, Mirbod P, Groene HJ, Koomagi R and Hollstein M: Unusual profile and high prevalence of p53 mutations in esophageal squamous cell carcinomas from northern Iran. Cancer Res. 61:3119–3123. 2001.
22	Guimaraes DP and Hainaut P: TP53: a key gene in human cancer. Biochimie. 84:83–93. 2002.
23	Taghavi N, Biramijamal F, Sotoudeh M, et al: Association of p53/p21 expression with cigarette smoking and prognosis in esophageal squamous cell carcinoma patients. World J Gastroenterol. 16:4958–4967. 2010.
24	Chiarugi V and Ruggiero M: Role of three cancer ‘master genes’ p53, bcl2 and c-myc on the apoptotic process. Tumori. 82:205–209. 1996.
25	Huerta S, Gao X, Dineen S, Kapur P, Saha D and Meyer J: Role of p53, Bax, p21, and DNA-PKcs in radiation sensitivity of HCT-116 cells and xenografts. Surgery. 154:143–151. 2013.
26	Jung SY, Jeong J, Shin SH, et al: Accumulation of p53 determined by immunohistochemistry as a prognostic marker in node negative breast cancer; analysis according to St Gallen consensus and intrinsic subtypes. J Surg Oncol. 103:207–211. 2011.
27	Koshiyama M, Konishi I, Wang DP, et al: Immunohistochemical analysis of p53 protein over-expression in endometrial carcinomas: inverse correlation with sex steroid receptor status. Virchows Arch A Pathol Anat Histopathol. 423:265–271. 1993.
28	Zhu HB, Yang K, Xie YQ, Lin YW, Mao QQ and Xie LP: Silencing of mutant p53 by siRNA induces cell cycle arrest and apoptosis in human bladder cancer cells. World J Surg Oncol. 11:222013.
29	Chava S, Mohan V, Shetty PJ, et al: Immunohistochemical evaluation of p53, FHIT, and IGF2 gene expression in esophageal cancer. Dis Esophagus. 25:81–87. 2012.
30	Launoy G, Milan C, Day NE, Pienkowski MP, Gignoux M and Faivre J: Diet and squamous-cell cancer of the oesophagus: a French multicentre case-control study. Int J Cancer. 76:7–12. 1998.
31	Sammon AM and Alderson D: Diet, reflux and the development of squamous cell carcinoma of the oesophagus in Africa. Br J Surg. 85:891–896. 1998.
32	Morse DE, Pendrys DG, Katz RV, et al: Food group intake and the risk of oral epithelial dysplasia in a United States population. Cancer Causes Control. 11:713–720. 2000.
33	Mizobuchi S, Furihata M, Sonobe H, et al: Association between p53 immunostaining and cigarette smoking in squamous cell carcinoma of the esophagus. Jpn J Clin Oncol. 30:423–428. 2000.